#None #Harbour BioMed #Youchen Chen #Ian Y. Liu

Strategic Leadership Expansion at Harbour BioMed

In a significant move to strengthen its executive leadership, Harbour BioMed, a global biopharmaceutical company based in Cambridge, Rotterdam, and Shanghai, has appointed Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors. This announcement, made on August 27, 2026, aims to enhance the alignment between the Company's Board of Directors and the management team, ensuring effective strategic execution and sustainable growth in the biopharmaceutical sector.

Who Are the New Executive Directors?

Youchen Chen has been pivotal in Harbour BioMed as the Chief Financial Officer since joining in 2023. His vast experience, nearly 15 years, includes financial management and business development in the biopharmaceutical industry. Before his tenure at Harbour BioMed, Chen held the position of CFO at a clinical-stage radiopharmaceutical startup. With a background as Vice President at Credit Suisse's Investment Banking sector, he brings valuable expertise in capital market strategies and investor relations. Chen's academic credentials include a law degree from Fudan University and an MBA from the McDonough School of Business at Georgetown University.

On the other hand, Dr. Ian Y. Liu, who serves as Senior Vice President and Global Head of Legal, has amassed over 20 years of experience covering global legal affairs in the biopharmaceutical field. Dr. Liu has not only managed critical legal matters and compliance but has also developed intellectual property strategies to safeguard the Company's innovations. Before joining Harbour BioMed, he worked with prominent law firms and served in executive legal roles for companies like Simcere Pharmaceutical. His academic journey includes a Bachelor of Science from Fudan University, a Ph.D. from Worcester Polytechnic Institute, and a J.D. from Suffolk University Law School.

Strategic Vision for the Future

Dr. Jingsong Wang, the Founder and CEO of Harbour BioMed, expressed excitement about the new appointments, emphasizing that both Chen and Liu have already made significant contributions and will bring diverse perspectives to strategic decision-making. With their leadership, Harbour BioMed aims to propel itself toward becoming a leading global biopharmaceutical entity focused on innovative drug discovery.

Mr. Chen commented on his new role, emphasizing the honor it is to participate in corporate governance and strategic decision-making. He envisions working closely with the Board to optimize the Company's financial and capital market strategies, with a long-term goal of positioning Harbour BioMed as a prominent platform-based biopharmaceutical group by 2028.

Likewise, Dr. Liu highlighted his commitment to sustaining Harbour BioMed's innovative edge in drug development. His focus will continue to be on ensuring legal compliance while supporting the Company's globalization efforts.

About Harbour BioMed

Founded on the principles of innovation, Harbour BioMed specializes in the discovery and development of novel antibody therapeutics, with a strong emphasis on immunology and oncology. The Company's proprietary antibody technology platform, Harbour Mice®, enables it to create fully human monoclonal antibodies with the potential to revolutionize treatment options. Through strategic global collaborations and internal R&D capabilities, Harbour BioMed is building a robust portfolio aimed at addressing significant medical needs.

As it continues to build upon its innovative technologies, such as the HCAb-based bispecific antibody technology and AI-powered models, Harbour BioMed is well-positioned to advance its mission of delivering next-generation therapeutic antibodies to the market.

For more details on their latest news and developments, visit their official website at www.harbourbiomed.com.